WO2014141035A3 - Fused heterocyclyl derivatives as nampt inhibitors - Google Patents

Fused heterocyclyl derivatives as nampt inhibitors Download PDF

Info

Publication number
WO2014141035A3
WO2014141035A3 PCT/IB2014/059582 IB2014059582W WO2014141035A3 WO 2014141035 A3 WO2014141035 A3 WO 2014141035A3 IB 2014059582 W IB2014059582 W IB 2014059582W WO 2014141035 A3 WO2014141035 A3 WO 2014141035A3
Authority
WO
WIPO (PCT)
Prior art keywords
heterocyclyl derivatives
fused heterocyclyl
nampt
nampt inhibitors
formula
Prior art date
Application number
PCT/IB2014/059582
Other languages
French (fr)
Other versions
WO2014141035A2 (en
Inventor
Dinesh Chikkanna
Vinayak Khairnar
Original Assignee
Aurigene Discovery Technologies Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Technologies Limited filed Critical Aurigene Discovery Technologies Limited
Publication of WO2014141035A2 publication Critical patent/WO2014141035A2/en
Publication of WO2014141035A3 publication Critical patent/WO2014141035A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

Provided are substituted heterocyclyl derivatives of formula (I), which may be the therapeutically useful, more particularly as NAMPT inhibitors; in which R 1, R 2, X 1, X 2, ring A, L and 'n' have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPT) in a mammal. Also provided are preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted fused heterocyclyl derivatives of formula (I) or pharmaceutically acceptable salts or stereoisomers thereof.
PCT/IB2014/059582 2013-03-11 2014-03-10 Fused heterocyclyl derivatives as nampt inhibitors WO2014141035A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1024/CHE/2013 2013-03-11
IN1024CH2013 2013-03-11

Publications (2)

Publication Number Publication Date
WO2014141035A2 WO2014141035A2 (en) 2014-09-18
WO2014141035A3 true WO2014141035A3 (en) 2015-04-09

Family

ID=51538222

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/059582 WO2014141035A2 (en) 2013-03-11 2014-03-10 Fused heterocyclyl derivatives as nampt inhibitors

Country Status (1)

Country Link
WO (1) WO2014141035A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016049774A1 (en) * 2014-10-03 2016-04-07 The Royal Institution For The Advancement Of Learning/Mcgill University Urea and bis-urea based compounds and analogues thereof useful in the treatment of androgen receptor mediated diseases or disorders
US10702506B2 (en) 2016-02-26 2020-07-07 The Regents Of The University Of California Small molecule inhibitors of pendrin ion exchange and pharmaceutical compositions
JP2022506351A (en) * 2018-11-02 2022-01-17 アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト A novel urea 6,7-dihydro-4H-thiazolo [5,4-C] pyridine with activity against hepatitis B virus (HBV)
CN115038688A (en) 2019-09-11 2022-09-09 文森雷生物科学股份有限公司 USP30 inhibitors and uses thereof
WO2023187391A1 (en) * 2022-03-31 2023-10-05 Pathios Therapeutics Limited 3,4,6,7-tetrahydro-2,7-naphthyridine-2(1h)-carboxamide derivatives as gpr65 inhibitors for the treatment of cancer and autoimmune diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012031199A1 (en) * 2010-09-03 2012-03-08 Forma Therapeutics, Inc. Guanidine compounds and compositions for the inhibition of nampt
WO2012067965A1 (en) * 2010-11-15 2012-05-24 Abbott Laboratories Nampt and rock inhibitors
WO2012067963A1 (en) * 2010-11-15 2012-05-24 Abbott Laboratories Nampt inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012031199A1 (en) * 2010-09-03 2012-03-08 Forma Therapeutics, Inc. Guanidine compounds and compositions for the inhibition of nampt
WO2012067965A1 (en) * 2010-11-15 2012-05-24 Abbott Laboratories Nampt and rock inhibitors
WO2012067963A1 (en) * 2010-11-15 2012-05-24 Abbott Laboratories Nampt inhibitors

Also Published As

Publication number Publication date
WO2014141035A2 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
MX2020010484A (en) Substituted heterocyclyl derivatives as cdk inhibitors.
PH12016501355A1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
SA518392101B1 (en) Benzimidazole Derivatives as Modulators of ROR-GAMMA
PH12016500024A1 (en) Bromodomain inhibitor
PH12015502004A1 (en) Tetracyclic bromodomain inhibitors
WO2016142855A3 (en) Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
EA033689B9 (en) Inhibitors of kras g12c
PH12017500029A1 (en) 4,5-dihydroisoxazole derivatives as nampt inhibitors
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
TN2016000090A1 (en) Substituted quinolizine derivatives useful as hiv integrase inhibitors.
MX2015012158A (en) Fused tetracyclic bromodomain inhibitors.
MX2016010056A (en) 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof.
UA109868C2 (en) N -alkyltriazole compounds asr
MX368903B (en) THERAPEUTIC COMPOUNDS and USES THEREOF.
WO2014155300A3 (en) Substitued pyrimidine amine derivatives as tak-1 inhibitors
MX2016007440A (en) Bromodomain inhibitors.
ATE536172T1 (en) EZETIMIBE COMPOSITIONS
WO2014141035A3 (en) Fused heterocyclyl derivatives as nampt inhibitors
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
TN2016000489A1 (en) Carboxamide derivatives.
WO2014016754A3 (en) Pharmaceutical compositions of proton pump inhibitor
MX2016009621A (en) Furo-3-carboxamide derivatives and methods of use.
MX2017013099A (en) Methods for the treatment of inflammatory disorders.
MX2017008495A (en) New benzimidazole derivatives as antihistamine agents.
PH12018501285A1 (en) Alkyl dihydroquinoline sulfonamide compounds

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 14764875

Country of ref document: EP

Kind code of ref document: A2